Eligard
Drug
TOLMAR, INC.
Total Payments
$54,537
Transactions
8
Doctors
2
Companies
1
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2020 | $3,000 | 1 | 1 |
| 2019 | $51,537 | 7 | 1 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $48,537 | 6 | 89.0% |
| Honoraria | $6,000 | 2 | 11.0% |
Payments by Type
Research
$48,537
6 transactions
General
$6,000
2 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| TOL2581A | TOLMAR, INC. | $48,537 | 0 |
Ad
Manufacturing Companies
- TOLMAR, INC. $54,537
Product Information
- Type Drug
- Total Payments $54,537
- Total Doctors 2
- Transactions 8
About Eligard
Eligard is a drug associated with $54,537 in payments to 2 healthcare providers, recorded across 8 transactions in the CMS Open Payments database. The primary manufacturer is TOLMAR, INC..
Payment data is available from 2019 to 2020. In 2020, $3,000 was paid across 1 transactions to 1 doctors.
The most common payment nature for Eligard is "Unspecified" ($48,537, 89.0% of total).
Eligard is associated with 1 research study, including "TOL2581A" ($48,537).